Henry Ford Health System is partnering with Janssen Pharmaceuticals to carry out the third phase of a COVID-19 vaccine trial. The Metro Detroit health system is one of three sites in Michigan, and one of many around the world, that will test the “safety and efficacy” of a single dose of Janssen’s potential COVID-19 vaccine, also known as JNJ-78436735 or Ad26.COV2.S, officials said. The clinical study, also called the “ENSEMBLE trial," is recruiting individuals who are not immunocompromised to receive either a single dose of the investigational vaccine or a placebo. Participating health systems in the U.S. and around the world are expected to recruit about 60,000 adults to carry out the third phase of the COVID vaccine trial. Related NewsAstraZeneca to deliver vaccine trial data by year’s endFeds issue coverage plan for COVID-19 vaccine and treatmentsProtests in Brazil support president in anti-vaccine stanceNearly 2.4 million Michigan residents have received flu vaccine this season